PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
35.89
-0.08 (-0.22%)
At close: 4:02PM EDT

35.99 +0.10 (0.28%)
After hours: 6:34PM EDT

Stock chart is not supported by your current browser
Previous Close35.97
Open35.96
Bid35.40 x 800
Ask0.00 x 800
Day's Range35.77 - 36.09
52 Week Range31.67 - 39.43
Volume16,625,330
Avg. Volume21,758,982
Market Cap209.941B
Beta0.95
PE Ratio (TTM)9.97
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.36 (3.82%)
Ex-Dividend Date2018-05-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters30 minutes ago

    Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe

    The U.S. Department of Justice said on Thursday that the civil settlement resolves allegations that Pfizer improperly used the Patient Access Network Foundation as a conduit to cover co-payment obligations of patients taking three Pfizer drugs. Pfizer's actions enabled the New York-based drugmaker to boost prices and revenue, violating the federal False Claims Act in a scheme that ran from 2012 to 2016, the department said.

  • The Wall Street Journal1 hour ago

    [$$] Pfizer to Pay $24 Million to Settle Probe Into Copay Assistance Charities

    Pfizer Inc. has agreed to pay nearly $24 million to resolve allegations that it violated federal law by using a charity to pay Medicare patients’ out-of-pocket costs for the company’s prescription drugs, federal prosecutors said. The settlement, with the U.S. Attorney’s Office in Boston, resolves allegations stemming from an investigation into charities that help patients pay for prescription drugs using donations from pharmaceutical companies.

  • Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe
    Reuters5 hours ago

    Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe

    The U.S. Department of Justice said on Thursday that the civil settlement resolves allegations that Pfizer improperly used the Patient Access Network Foundation as a conduit to cover co-payment obligations of patients taking three Pfizer drugs. Pfizer's actions enabled the New York-based drugmaker to boost prices and revenue, violating the federal False Claims Act in a scheme that ran from 2012 to 2016, the department said.

  • Pfizer Used Charity to Mask Heart Drug Price Hikes, U.S. Says
    Bloomberg8 hours ago

    Pfizer Used Charity to Mask Heart Drug Price Hikes, U.S. Says

    Pfizer Inc. used a “purportedly independent” charity to help it sharply raise the price of a heart drug, shielding patients from the increase while Medicare picked up the higher costs, the U.S. Justice Department said Thursday in a civil settlement announcement. Pfizer will pay about $24 million in the anti-kickback settlement, the government said in a statement.

  • MarketWatch10 hours ago

    Pfizer to pay $23.85 million to settle kickback allegations

    The Department of Justice said on Thursday that global pharmaceutical company Pfizer, Inc. settled allegations that it used a foundation as a conduit to pay the copays of Medicare patients taking three Pfizer drugs, in violation of the False Claims Act, and will pay $23.85 million to resolve the claims. Under the Anti-Kickback Statute, pharmaceutical companies are prohibited from offering, directly or indirectly, any payment-which includes paying patients' copay obligations-to induce Medicare patients to purchase the company's drugs.

  • Pfizer's Tafamadis Gets Breakthrough Therapy Designation
    Zacks11 hours ago

    Pfizer's Tafamadis Gets Breakthrough Therapy Designation

    Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.

  • Pfizer’s Growth Drivers in Q1 2018
    Market Realist11 hours ago

    Pfizer’s Growth Drivers in Q1 2018

    As we’ve already seen, Pfizer’s (PFE) products are segregated into two segments: Innovative Health and Essential Health. These products were Pfizer’s growth drivers in the first segment: BMP2, Chantix/Champix, Eliquis, Genotropin, Ibrance, Lipitor, Norvasc, Sulperazon, Sutent, Xalkori, Xeljanz, Xtandi, and a few others.

  • Reuters11 hours ago

    Drug maker Pfizer to pay $23.85 mln to settle claims it paid kickbacks

    Drug maker Pfizer will pay $23.85 million to settle civil charges that it illegally paid kickbacks by using a foundation as a "conduit" to cover co-pay costs for Medicare patients taking three of the company's drugs, the U.S. Justice Department said Thursday. As part of the settlement, the company will also enter a corporate integrity agreement with the inspector general for the Department of Health and Human Services, which will require the company to implement new compliance measures.

  • InvestorPlace11 hours ago

    3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More

    A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.

  • 3 Big Pharma Stocks with Huge Future Growth Potential
    InvestorPlace12 hours ago

    3 Big Pharma Stocks with Huge Future Growth Potential

    You might not be aware of it, but big pharma stocks have gone through a difficult period for many years. A lot of the big drugs at the big pharma stocks went off patent, and the revenue for some of the big pharma stocks has fallen off as a result. Some of the big pharma stocks were able to replace that revenue and some weren’t.

  • Pfizer’s Performance across Geographies in Q1 2018
    Market Realist13 hours ago

    Pfizer’s Performance across Geographies in Q1 2018

    As we’ve already seen, Pfizer’s (PFE) revenues increased 1% to $12.9 billion in the first quarter, driven by increased sales of its Innovative Health products. Pfizer reported a decrease of 5% in US sales in the first quarter. For the first quarter, the Innovative Health segment reported growth of 1% in revenues to $4.5 billion, while the Essential Health segment reported a 19% decline in revenues to $1.7 billion.

  • Pfizer’s Segment Performances in Q1 2018
    Market Realist14 hours ago

    Pfizer’s Segment Performances in Q1 2018

    Pfizer’s (PFE) business is segregated into two segments: Innovative Health and Essential Health. The above chart compares the revenue trend for Pfizer since Q1 2017. The Innovative Health segment reported a 6% growth in revenues to $7.8 billion in the first quarter.

  • Financial Times22 hours ago

    [$$] Pfizer under pressure to resolve shortage of life-saving EpiPen

    to do more to tackle shortages of the life-saving medicine in a sign of its growing frustration with the Big Pharma company. Although Mylan owns the rights to the EpiPen — which can stave off deadly anaphylactic shock — it subcontracts manufacturing of the auto-injector to Meridian Medical, a division of Pfizer. The US Food and Drug Administration put the medicine on its official shortages list earlier this month.

  • Financial Times23 hours ago

    [$$] Pfizer agrees to pay nearly $24m to settle kickback claims

    has agreed to pay almost $24m to settle claims it paid kickbacks to Medicare patients who used its medications, the US Department of Justice said on Thursday. The pharmaceutical company allegedly used a third-party foundation to route payments to patients using three Pfizer drugs, according to the DOJ. Patients using the US Medicare system have some of the cost of treatment paid for by the government, but also have to make a partial “co-pay” payment.

  • TheStreet.comyesterday

    Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

    The pharma industry spent $3.45 billion on television ads in 2017 and none of those ads mentioned drug prices. The Trump administration wants to change that. In his Rose Garden speech earlier this month, President Trump suggested that direct-to-consumer ads include mandatory pricing information along with risk issues and other educational information.

  • Pfizer’s Quarterly Revenue Trend in Q1 2018
    Market Realistyesterday

    Pfizer’s Quarterly Revenue Trend in Q1 2018

    Pfizer (PFE) reported revenues of $12.9 billion for the first quarter, which was a 1% growth compared to $12.8 million in Q1 2017. The growth in revenues was driven by a strong performance of its Innovative Health segment, partially offset by lower sales of its Essential Health products.

  • Analyst Recommendations for Pfizer on May 22
    Market Realistyesterday

    Analyst Recommendations for Pfizer on May 22

    Wall Street analysts estimate that Pfizer’s (PFE) top line will increase 1% to $13.7 billion in the second quarter. For the second quarter, analysts estimate that Pfizer will report 3.5% growth in revenues to $13.4 billion compared to $12.9 billion in Q2 2017. Pfizer stock has risen 10.3% over the last 12 months but has fallen 1.2% year-to-date.

  • Pfizer’s Valuation as of May 22
    Market Realistyesterday

    Pfizer’s Valuation as of May 22

    Pfizer (PFE) reported a 1% growth in revenues to $12.9 billion in the first quarter compared to $12.8 billion in the first quarter of 2017. It surpassed Wall Street analysts’ estimate for EPS but missed the revenue estimate. It reported EPS of $0.77 on revenues of $12.9 billion compared to the EPS estimate of $0.74 on revenues of $13.1 billion.

  • Better Buy: AbbVie Inc. vs. Pfizer Inc.
    Motley Fool2 days ago

    Better Buy: AbbVie Inc. vs. Pfizer Inc.

    Which big pharma stock wins in a head-to-head match-up?

  • How Are Tesaro’s Valuations and Cash Flows?
    Market Realist2 days ago

    How Are Tesaro’s Valuations and Cash Flows?

    Tesaro used $147.6 million in operating activities in the first quarter—compared to $114.6 million in the first quarter of 2017. The company used $1.6 million in investing activities in the first quarter—compared to $1.8 million in the first quarter of 2017. The expense was mainly for purchasing property and equipment related to Tesaro expanding leased premises at its headquarters.

  • Tesaro Stock: What’s the Upside Potential?
    Market Realist2 days ago

    Tesaro Stock: What’s the Upside Potential?

    Tesaro (TSRO) is a commercial stage biopharmaceutical company focused on developing treatments for solid tumors. Tesaro is licensed and developing a number of oncology-related product candidates. Of the 19 analysts covering Tesaro in May, 12 analysts gave the stock a “buy” or higher rating, while seven analysts gave a “hold” rating.

  • Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?
    Market Realist2 days ago

    Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?

    Late last week, Johnson & Johnson (JNJ) announced that it was scrapping its mid-stage trial for the development of the treatment of Alzheimer’s disease, EARLY, which was in Phase 2b/3. The trial was testing the BACE inhibitor atabecestat. Johnson & Johnson is the latest in a series of companies, including Pfizer (PFE), Merck & Company (MRK), and Eli Lilly and Company (LLY), that have abandoned trials for their Alzheimer’s drug candidates.

  • Spark, Pfizer report progress on gene therapy for hemophilia
    American City Business Journals2 days ago

    Spark, Pfizer report progress on gene therapy for hemophilia

    The clinical testing program is expected to transition to Pfizer from Spark Therapeutics this summer.

  • Wall Street Sees Upside of More than 17% for JNJ in the Next Year
    Market Realist2 days ago

    Wall Street Sees Upside of More than 17% for JNJ in the Next Year

    Over the last few quarters, Johnson & Johnson (JNJ) has seen a number of factors affecting investor sentiments surrounding its stock. The company, however, posted strong results for the first quarter on April 17, exceeding analysts’ estimates. In this article, we’ll take a look at analysts’ recommendations on JNJ for the next 12 months.

  • Gauging the Upside Potential of Vertex Pharmaceuticals Stock
    Market Realist2 days ago

    Gauging the Upside Potential of Vertex Pharmaceuticals Stock

    Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies for treating cystic fibrosis (or CF) and advancing research and development programs for other diseases. Of the 25 analysts covering Vertex Pharmaceuticals in May, 21 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.76 with a target price of $191.39, implying an upside of 22.6% over its closing price of $156.16 on May 16. Of the 26 analysts covering Gilead Sciences (GILD) in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.15 with a target price of $85.81.